Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients

被引:18
作者
Funke, Claudia [2 ]
Soehn, Anne S. [2 ]
Tomiuk, Juergen [2 ]
Riess, Olaf [2 ]
Berg, Daniela [1 ]
机构
[1] Univ Tubingen, Dept Neurodegenerat, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Med Genet, Tubingen, Germany
关键词
Parkinson's disease; Blood-brain barrier; P-glycoprotein; SNaPshot; Single nucleotide polymorphism; Case-control study; P-GLYCOPROTEIN FUNCTION; TRANSCRANIAL ULTRASOUND; SUBSTANTIA-NIGRA; ECHOGENICITY; POLYMORPHISM; ASSOCIATION;
D O I
10.1007/s00702-009-0196-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons and the presence of intracytoplasmic inclusions (Lewy bodies). Iron, which is elevated in the substantia nigra of PD patients, seems to be of pivotal importance, because of its capacity to enhance the amplification of reactive oxygen species. As iron enters and exits the brain via transport proteins in the blood-brain barrier (BBB), these proteins may represent candidates for a genetic susceptibility to PD. P-glycoprotein (P-gp) is one important efflux pump in the BBB. There is evidence that the function of P-gp is impaired in PD patients. In the current study we examined ten coding single nucleotide polymorphisms in the multidrug resistance gene 1 (MDR1) encoding P-gp to assess whether certain genotypes are associated with PD. However, genotyping of 300 PD patients and 302 healthy controls did not reveal a significant association between coding MDR1 gene polymorphisms and PD.
引用
收藏
页码:443 / 450
页数:8
相关论文
共 24 条
[1]
Bain LJ, 1996, TOXICOL APPL PHARM, V141, P288, DOI 10.1016/S0041-008X(96)80035-4
[2]
Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease [J].
Bartels, A. L. ;
van Berckel, B. N. M. ;
Lubberink, M. ;
Luurtsema, G. ;
Lammertsma, A. A. ;
Leenders, K. L. .
PARKINSONISM & RELATED DISORDERS, 2008, 14 (06) :505-508
[3]
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA [J].
Bartels, A. L. ;
Willemsen, A. T. M. ;
Kortekaas, R. ;
de Jong, B. M. ;
de Vries, R. ;
de Klerk, O. ;
van Oostrom, J. C. H. ;
Portman, A. ;
Leenders, K. L. .
JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (07) :1001-1009
[4]
Berg D, 2006, J NEURAL TRANSM-SUPP, P249
[5]
Disturbance of iron metabolism in Parkinson's disease ultrasonography as a biomarker [J].
Berg, D ;
Hochstrasser, H ;
Schweitzer, KJ ;
Riess, O .
NEUROTOXICITY RESEARCH, 2006, 9 (01) :1-13
[6]
Echogenicity of the substantia nigra -: Association with increased iron content and marker for susceptibility to nigrostriatal injury [J].
Berg, D ;
Roggendorf, W ;
Schröder, U ;
Klein, R ;
Tatschner, T ;
Benz, P ;
Tucha, O ;
Preier, M ;
Lange, KW ;
Reiners, K ;
Gerlach, M ;
Becker, G .
ARCHIVES OF NEUROLOGY, 2002, 59 (06) :999-1005
[7]
Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy [J].
Berg, D ;
Jabs, B ;
Merschdorf, U ;
Beckmann, H ;
Becker, G .
BIOLOGICAL PSYCHIATRY, 2001, 50 (06) :463-467
[8]
Brain iron pathways and their relevance to Parkinson's disease [J].
Berg, D ;
Gerlach, M ;
Youdim, MBH ;
Double, KL ;
Zecca, L ;
Riederer, P ;
Becker, G .
JOURNAL OF NEUROCHEMISTRY, 2001, 79 (02) :225-236
[9]
Vulnerability of the nigrostriatal system as detected by transcranial ultrasound [J].
Berg, D ;
Becker, G ;
Zeiler, B ;
Tucha, O ;
Hofmann, E ;
Preier, M ;
Benz, P ;
Jost, W ;
Reiners, K ;
Lange, KW .
NEUROLOGY, 1999, 53 (05) :1026-1031
[10]
Association study between iron-related genes polymorphisms and Parkinson's disease [J].
Borie, C ;
Gasparini, F ;
Verpillat, P ;
Bonnet, AM ;
Agid, Y ;
Hetet, G ;
Brice, A ;
Dürr, A ;
Grandchamp, B .
JOURNAL OF NEUROLOGY, 2002, 249 (07) :801-804